循環腫瘍細胞市場：検体別、技術別、製品別、用途別-2025-2030年の世界予測

循環腫瘍細胞市場は、2023年に124億4,000万米ドルと評価され、2024年には141億7,000万米ドルに達すると予想され、2030年には311億2,000万米ドルにまで13.99%のCAGRで成長すると予測されています。

循環腫瘍細胞（CTC）は、がんの診断、予後、治療効果の予測を大幅に向上させる重要な非侵襲的バイオマーカーです。CTC分析市場は、がんの早期発見、個別化医療、疾患モニタリングアプリケーションの緊急の必要性によって牽引されており、精密医療へのシフトを考えると特に有望です。病院、診断研究所、研究機関などの最終用途部門は、従来の生検法に取って代わる可能性があるCTC技術を追求しています。主な成長促進要因は、がん罹患率の上昇、検出技術の進歩、研究投資の増加などです。市場は、CTC検出を改善するための人工知能の活用や、予測分析のための包括的データベースの構築において急成長する機会を目の当たりにしています。とはいえ、高コスト、技術的複雑性、標準化の問題などの課題が、市場成長の大きな障壁となっています。検出技術の感度と特異度が限定的であることも依然としてハードルであり、しばしば検出不足や偽陽性につながります。さらに、規制や倫理的配慮が市場力学に大きく影響し、承認や市場参入を複雑にしています。このような課題にもかかわらず、費用対効果の高い高感度検出法の開発や、包括的な知見を得るためのマルチオミクス・アプローチの統合には、技術革新の機会があふれています。マイクロ流体工学、ナノテクノロジー、分子アッセイの進歩における革新は、市場拡大を推進しうる有望な分野として認識されています。さらに、バイオテクノロジー企業、研究機関、ヘルスケアプロバイダー間の戦略的協力関係を促進することで、より広範な技術導入と強固なプロトコル開発が促進される可能性があります。さらに、ポリマーベースの捕捉物質や疾患管理用の統合プラットフォームの出現は、潜在的な成長の道を示しています。全体として、CTC市場は急速な技術進歩と多様な応用分野を特徴とするダイナミックな性質を持っているが、市場の持続可能性は、新たなブレークスルーを活用しながら現在の限界に対処し、臨床結果と市場浸透を高めるパートナーシップを形成することにかかっています。市場関係者は、こうした進化する機会を活用するために機敏性を維持する必要があります。

市場力学：急速に進化する循環腫瘍細胞市場の主要市場インサイトを公開

循環腫瘍細胞市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • がん関連治療への支出の増加
  • 全世界におけるがんの有病率
  • がんの早期発見に対する意識の高まりと注目
• 市場抑制要因
  • CTCシステムに関する認識不足
• 市場機会
  • 生物工学と生物医学の技術的進歩
  • 近年の低侵襲診断への需要
• 市場の課題
  • CTC技術の承認に関する政府の厳しい規制

ポーターの5つの力：循環腫瘍細胞市場をナビゲートする戦略ツール

ポーターの5つの力」フレームワークは、市場情勢の競合情勢を把握するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：循環腫瘍細胞市場における外部からの影響の把握

外部マクロ環境要因は、循環腫瘍細胞市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析循環腫瘍細胞市場における競合情勢の把握

循環腫瘍細胞市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス循環腫瘍細胞市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、循環腫瘍細胞市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨循環腫瘍細胞市場における成功への道筋を描く

循環腫瘍細胞市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • がん関連治療への支出増加
    • 世界中のがんの罹患率
    • がんの早期発見に対する意識の高まりと注目
  • 抑制要因
    • CTCシステムに関する認識不足
  • 機会
    • バイオエンジニアリングとバイオメディカルの実践における技術的進歩
    • 近年の低侵襲診断の需要
  • 課題
    • CTC技術の承認に関する厳格な政府規制
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 循環腫瘍細胞市場標本別

• 血
• 骨髄

第7章 循環腫瘍細胞市場：技術別

• CTC分析
• CTC検出および濃縮方法
  • 複合的な方法
  • 密度に基づく分離
  • 免疫捕捉
    • ネガティブな選択
    • ポジティブセレクション
  • サイズに基づく分離
    • 膜ベース
    • マイクロ流体ベース
• CTC直接検出法
  • 顕微鏡検査
  • サーズ

第8章 循環腫瘍細胞市場：製品別

• 採血管
• デバイスまたはシステム
• キットと試薬

第9章 循環腫瘍細胞市場：用途別

• 臨床/液体生検
  • リスクアセスメント
  • スクリーニングとモニタリング
• 調査
  • がん幹細胞と腫瘍形成調査
  • 医薬品または治療法の開発

第10章 南北アメリカの循環腫瘍細胞市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋地域の循環腫瘍細胞市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカの循環腫瘍細胞市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• BioFluidica
• Biolidics Limited
• Creatv MicroTech, Inc.
• Epic Sciences
• Fluxion Biosciences, Inc.
• Greiner Bio One International GmbH
• Ikonisys Inc.
• IVDiagnostics
• LungLife AI, Inc.
• Menarini Silicon Biosystems
• Miltenyi Biotec GmbH
• NanoString Technologies, Inc.
• Precision Medicine Group, LLC
• QIAGEN GmbH
• Rarecells Diagnostics
• ScreenCell
• STEMCELL Technologies, Inc.
• Sysmex Corporation
• Vitatex, Inc

LIST OF FIGURES

• FIGURE 1. CIRCULATING TUMOR CELL MARKET RESEARCH PROCESS
• FIGURE 2. CIRCULATING TUMOR CELL MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY SPECIMEN, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY SPECIMEN, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. AMERICAS CIRCULATING TUMOR CELL MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. AMERICAS CIRCULATING TUMOR CELL MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. UNITED STATES CIRCULATING TUMOR CELL MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 17. UNITED STATES CIRCULATING TUMOR CELL MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC CIRCULATING TUMOR CELL MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. ASIA-PACIFIC CIRCULATING TUMOR CELL MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CIRCULATING TUMOR CELL MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CIRCULATING TUMOR CELL MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. CIRCULATING TUMOR CELL MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 23. CIRCULATING TUMOR CELL MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. CIRCULATING TUMOR CELL MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. CIRCULATING TUMOR CELL MARKET DYNAMICS
• TABLE 7. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY BLOOD, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY BONE MARROW, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY CTC ANALYSIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ENRICHMENT METHODS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY COMBINED METHODS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY DENSITY-BASED SEPARATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY IMMUNOCAPTURE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY NEGATIVE SELECTION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY POSITIVE SELECTION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY IMMUNOCAPTURE, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY SIZE-BASED SEPARATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY MEMBRANE-BASED, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY MICROFLUIDIC-BASED, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY SIZE-BASED SEPARATION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ENRICHMENT METHODS, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DIRECT DETECTION METHODS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY MICROSCOPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY SERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DIRECT DETECTION METHODS, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY BLOOD COLLECTION TUBES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY DEVICES OR SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY KITS & REAGENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY CLINICAL/ LIQUID BIOPSY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 34. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY RISK ASSESSMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 35. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY SCREENING & MONITORING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 36. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY CLINICAL/ LIQUID BIOPSY, 2018-2030 (USD MILLION)
• TABLE 37. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY RESEARCH, BY REGION, 2018-2030 (USD MILLION)
• TABLE 38. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY CANCER STEM CELL & TUMORIGENESIS RESEARCH, BY REGION, 2018-2030 (USD MILLION)
• TABLE 39. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY DRUG OR THERAPY DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 40. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 41. AMERICAS CIRCULATING TUMOR CELL MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
• TABLE 42. AMERICAS CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 43. AMERICAS CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ENRICHMENT METHODS, 2018-2030 (USD MILLION)
• TABLE 44. AMERICAS CIRCULATING TUMOR CELL MARKET SIZE, BY IMMUNOCAPTURE, 2018-2030 (USD MILLION)
• TABLE 45. AMERICAS CIRCULATING TUMOR CELL MARKET SIZE, BY SIZE-BASED SEPARATION, 2018-2030 (USD MILLION)
• TABLE 46. AMERICAS CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DIRECT DETECTION METHODS, 2018-2030 (USD MILLION)
• TABLE 47. AMERICAS CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 48. AMERICAS CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 49. AMERICAS CIRCULATING TUMOR CELL MARKET SIZE, BY CLINICAL/ LIQUID BIOPSY, 2018-2030 (USD MILLION)
• TABLE 50. AMERICAS CIRCULATING TUMOR CELL MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 51. AMERICAS CIRCULATING TUMOR CELL MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 52. ARGENTINA CIRCULATING TUMOR CELL MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
• TABLE 53. ARGENTINA CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 54. ARGENTINA CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ENRICHMENT METHODS, 2018-2030 (USD MILLION)
• TABLE 55. ARGENTINA CIRCULATING TUMOR CELL MARKET SIZE, BY IMMUNOCAPTURE, 2018-2030 (USD MILLION)
• TABLE 56. ARGENTINA CIRCULATING TUMOR CELL MARKET SIZE, BY SIZE-BASED SEPARATION, 2018-2030 (USD MILLION)
• TABLE 57. ARGENTINA CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DIRECT DETECTION METHODS, 2018-2030 (USD MILLION)
• TABLE 58. ARGENTINA CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 59. ARGENTINA CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 60. ARGENTINA CIRCULATING TUMOR CELL MARKET SIZE, BY CLINICAL/ LIQUID BIOPSY, 2018-2030 (USD MILLION)
• TABLE 61. ARGENTINA CIRCULATING TUMOR CELL MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 62. BRAZIL CIRCULATING TUMOR CELL MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
• TABLE 63. BRAZIL CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 64. BRAZIL CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ENRICHMENT METHODS, 2018-2030 (USD MILLION)
• TABLE 65. BRAZIL CIRCULATING TUMOR CELL MARKET SIZE, BY IMMUNOCAPTURE, 2018-2030 (USD MILLION)
• TABLE 66. BRAZIL CIRCULATING TUMOR CELL MARKET SIZE, BY SIZE-BASED SEPARATION, 2018-2030 (USD MILLION)
• TABLE 67. BRAZIL CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DIRECT DETECTION METHODS, 2018-2030 (USD MILLION)
• TABLE 68. BRAZIL CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 69. BRAZIL CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 70. BRAZIL CIRCULATING TUMOR CELL MARKET SIZE, BY CLINICAL/ LIQUID BIOPSY, 2018-2030 (USD MILLION)
• TABLE 71. BRAZIL CIRCULATING TUMOR CELL MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 72. CANADA CIRCULATING TUMOR CELL MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
• TABLE 73. CANADA CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 74. CANADA CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ENRICHMENT METHODS, 2018-2030 (USD MILLION)
• TABLE 75. CANADA CIRCULATING TUMOR CELL MARKET SIZE, BY IMMUNOCAPTURE, 2018-2030 (USD MILLION)
• TABLE 76. CANADA CIRCULATING TUMOR CELL MARKET SIZE, BY SIZE-BASED SEPARATION, 2018-2030 (USD MILLION)
• TABLE 77. CANADA CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DIRECT DETECTION METHODS, 2018-2030 (USD MILLION)
• TABLE 78. CANADA CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 79. CANADA CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 80. CANADA CIRCULATING TUMOR CELL MARKET SIZE, BY CLINICAL/ LIQUID BIOPSY, 2018-2030 (USD MILLION)
• TABLE 81. CANADA CIRCULATING TUMOR CELL MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 82. MEXICO CIRCULATING TUMOR CELL MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
• TABLE 83. MEXICO CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 84. MEXICO CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ENRICHMENT METHODS, 2018-2030 (USD MILLION)
• TABLE 85. MEXICO CIRCULATING TUMOR CELL MARKET SIZE, BY IMMUNOCAPTURE, 2018-2030 (USD MILLION)
• TABLE 86. MEXICO CIRCULATING TUMOR CELL MARKET SIZE, BY SIZE-BASED SEPARATION, 2018-2030 (USD MILLION)
• TABLE 87. MEXICO CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DIRECT DETECTION METHODS, 2018-2030 (USD MILLION)
• TABLE 88. MEXICO CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 89. MEXICO CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 90. MEXICO CIRCULATING TUMOR CELL MARKET SIZE, BY CLINICAL/ LIQUID BIOPSY, 2018-2030 (USD MILLION)
• TABLE 91. MEXICO CIRCULATING TUMOR CELL MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 92. UNITED STATES CIRCULATING TUMOR CELL MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
• TABLE 93. UNITED STATES CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 94. UNITED STATES CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ENRICHMENT METHODS, 2018-2030 (USD MILLION)
• TABLE 95. UNITED STATES CIRCULATING TUMOR CELL MARKET SIZE, BY IMMUNOCAPTURE, 2018-2030 (USD MILLION)
• TABLE 96. UNITED STATES CIRCULATING TUMOR CELL MARKET SIZE, BY SIZE-BASED SEPARATION, 2018-2030 (USD MILLION)
• TABLE 97. UNITED STATES CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DIRECT DETECTION METHODS, 2018-2030 (USD MILLION)
• TABLE 98. UNITED STATES CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 99. UNITED STATES CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 100. UNITED STATES CIRCULATING TUMOR CELL MARKET SIZE, BY CLINICAL/ LIQUID BIOPSY, 2018-2030 (USD MILLION)
• TABLE 101. UNITED STATES CIRCULATING TUMOR CELL MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 102. UNITED STATES CIRCULATING TUMOR CELL MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 103. ASIA-PACIFIC CIRCULATING TUMOR CELL MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
• TABLE 104. ASIA-PACIFIC CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 105. ASIA-PACIFIC CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ENRICHMENT METHODS, 2018-2030 (USD MILLION)
• TABLE 106. ASIA-PACIFIC CIRCULATING TUMOR CELL MARKET SIZE, BY IMMUNOCAPTURE, 2018-2030 (USD MILLION)
• TABLE 107. ASIA-PACIFIC CIRCULATING TUMOR CELL MARKET SIZE, BY SIZE-BASED SEPARATION, 2018-2030 (USD MILLION)
• TABLE 108. ASIA-PACIFIC CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DIRECT DETECTION METHODS, 2018-2030 (USD MILLION)
• TABLE 109. ASIA-PACIFIC CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 110. ASIA-PACIFIC CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 111. ASIA-PACIFIC CIRCULATING TUMOR CELL MARKET SIZE, BY CLINICAL/ LIQUID BIOPSY, 2018-2030 (USD MILLION)
• TABLE 112. ASIA-PACIFIC CIRCULATING TUMOR CELL MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 113. ASIA-PACIFIC CIRCULATING TUMOR CELL MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 114. AUSTRALIA CIRCULATING TUMOR CELL MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
• TABLE 115. AUSTRALIA CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 116. AUSTRALIA CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ENRICHMENT METHODS, 2018-2030 (USD MILLION)
• TABLE 117. AUSTRALIA CIRCULATING TUMOR CELL MARKET SIZE, BY IMMUNOCAPTURE, 2018-2030 (USD MILLION)
• TABLE 118. AUSTRALIA CIRCULATING TUMOR CELL MARKET SIZE, BY SIZE-BASED SEPARATION, 2018-2030 (USD MILLION)
• TABLE 119. AUSTRALIA CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DIRECT DETECTION METHODS, 2018-2030 (USD MILLION)
• TABLE 120. AUSTRALIA CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 121. AUSTRALIA CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 122. AUSTRALIA CIRCULATING TUMOR CELL MARKET SIZE, BY CLINICAL/ LIQUID BIOPSY, 2018-2030 (USD MILLION)
• TABLE 123. AUSTRALIA CIRCULATING TUMOR CELL MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 124. CHINA CIRCULATING TUMOR CELL MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
• TABLE 125. CHINA CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 126. CHINA CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ENRICHMENT METHODS, 2018-2030 (USD MILLION)
• TABLE 127. CHINA CIRCULATING TUMOR CELL MARKET SIZE, BY IMMUNOCAPTURE, 2018-2030 (USD MILLION)
• TABLE 128. CHINA CIRCULATING TUMOR CELL MARKET SIZE, BY SIZE-BASED SEPARATION, 2018-2030 (USD MILLION)
• TABLE 129. CHINA CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DIRECT DETECTION METHODS, 2018-2030 (USD MILLION)
• TABLE 130. CHINA CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 131. CHINA CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 132. CHINA CIRCULATING TUMOR CELL MARKET SIZE, BY CLINICAL/ LIQUID BIOPSY, 2018-2030 (USD MILLION)
• TABLE 133. CHINA CIRCULATING TUMOR CELL MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 134. INDIA CIRCULATING TUMOR CELL MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
• TABLE 135. INDIA CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 136. INDIA CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ENRICHMENT METHODS, 2018-2030 (USD MILLION)
• TABLE 137. INDIA CIRCULATING TUMOR CELL MARKET SIZE, BY IMMUNOCAPTURE, 2018-2030 (USD MILLION)
• TABLE 138. INDIA CIRCULATING TUMOR CELL MARKET SIZE, BY SIZE-BASED SEPARATION, 2018-2030 (USD MILLION)
• TABLE 139. INDIA CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DIRECT DETECTION METHODS, 2018-2030 (USD MILLION)
• TABLE 140. INDIA CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 141. INDIA CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 142. INDIA CIRCULATING TUMOR CELL MARKET SIZE, BY CLINICAL/ LIQUID BIOPSY, 2018-2030 (USD MILLION)
• TABLE 143. INDIA CIRCULATING TUMOR CELL MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 144. INDONESIA CIRCULATING TUMOR CELL MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
• TABLE 145. INDONESIA CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 146. INDONESIA CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ENRICHMENT METHODS, 2018-2030 (USD MILLION)
• TABLE 147. INDONESIA CIRCULATING TUMOR CELL MARKET SIZE, BY IMMUNOCAPTURE, 2018-2030 (USD MILLION)
• TABLE 148. INDONESIA CIRCULATING TUMOR CELL MARKET SIZE, BY SIZE-BASED SEPARATION, 2018-2030 (USD MILLION)
• TABLE 149. INDONESIA CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DIRECT DETECTION METHODS, 2018-2030 (USD MILLION)
• TABLE 150. INDONESIA CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 151. INDONESIA CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 152. INDONESIA CIRCULATING TUMOR CELL MARKET SIZE, BY CLINICAL/ LIQUID BIOPSY, 2018-2030 (USD MILLION)
• TABLE 153. INDONESIA CIRCULATING TUMOR CELL MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 154. JAPAN CIRCULATING TUMOR CELL MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
• TABLE 155. JAPAN CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 156. JAPAN CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ENRICHMENT METHODS, 2018-2030 (USD MILLION)
• TABLE 157. JAPAN CIRCULATING TUMOR CELL MARKET SIZE, BY IMMUNOCAPTURE, 2018-2030 (USD MILLION)
• TABLE 158. JAPAN CIRCULATING TUMOR CELL MARKET SIZE, BY SIZE-BASED SEPARATION, 2018-2030 (USD MILLION)
• TABLE 159. JAPAN CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DIRECT DETECTION METHODS, 2018-2030 (USD MILLION)
• TABLE 160. JAPAN CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 161. JAPAN CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 162. JAPAN CIRCULATING TUMOR CELL MARKET SIZE, BY CLINICAL/ LIQUID BIOPSY, 2018-2030 (USD MILLION)
• TABLE 163. JAPAN CIRCULATING TUMOR CELL MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 164. MALAYSIA CIRCULATING TUMOR CELL MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
• TABLE 165. MALAYSIA CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 166. MALAYSIA CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ENRICHMENT METHODS, 2018-2030 (USD MILLION)
• TABLE 167. MALAYSIA CIRCULATING TUMOR CELL MARKET SIZE, BY IMMUNOCAPTURE, 2018-2030 (USD MILLION)
• TABLE 168. MALAYSIA CIRCULATING TUMOR CELL MARKET SIZE, BY SIZE-BASED SEPARATION, 2018-2030 (USD MILLION)
• TABLE 169. MALAYSIA CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DIRECT DETECTION METHODS, 2018-2030 (USD MILLION)
• TABLE 170. MALAYSIA CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 171. MALAYSIA CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 172. MALAYSIA CIRCULATING TUMOR CELL MARKET SIZE, BY CLINICAL/ LIQUID BIOPSY, 2018-2030 (USD MILLION)
• TABLE 173. MALAYSIA CIRCULATING TUMOR CELL MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 174. PHILIPPINES CIRCULATING TUMOR CELL MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
• TABLE 175. PHILIPPINES CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 176. PHILIPPINES CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ENRICHMENT METHODS, 2018-2030 (USD MILLION)
• TABLE 177. PHILIPPINES CIRCULATING TUMOR CELL MARKET SIZE, BY IMMUNOCAPTURE, 2018-2030 (USD MILLION)
• TABLE 178. PHILIPPINES CIRCULATING TUMOR CELL MARKET SIZE, BY SIZE-BASED SEPARATION, 2018-2030 (USD MILLION)
• TABLE 179. PHILIPPINES CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DIRECT DETECTION METHODS, 2018-2030 (USD MILLION)
• TABLE 180. PHILIPPINES CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 181. PHILIPPINES CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 182. PHILIPPINES CIRCULATING TUMOR CELL MARKET SIZE, BY CLINICAL/ LIQUID BIOPSY, 2018-2030 (USD MILLION)
• TABLE 183. PHILIPPINES CIRCULATING TUMOR CELL MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 184. SINGAPORE CIRCULATING TUMOR CELL MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
• TABLE 185. SINGAPORE CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 186. SINGAPORE CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ENRICHMENT METHODS, 2018-2030 (USD MILLION)
• TABLE 187. SINGAPORE CIRCULATING TUMOR CELL MARKET SIZE, BY IMMUNOCAPTURE, 2018-2030 (USD MILLION)
• TABLE 188. SINGAPORE CIRCULATING TUMOR CELL MARKET SIZE, BY SIZE-BASED SEPARATION, 2018-2030 (USD MILLION)
• TABLE 189. SINGAPORE CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DIRECT DETECTION METHODS, 2018-2030 (USD MILLION)
• TABLE 190. SINGAPORE CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 191. SINGAPORE CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 192. SINGAPORE CIRCULATING TUMOR CELL MARKET SIZE, BY CLINICAL/ LIQUID BIOPSY, 2018-2030 (USD MILLION)
• TABLE 193. SINGAPORE CIRCULATING TUMOR CELL MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 194. SOUTH KOREA CIRCULATING TUMOR CELL MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
• TABLE 195. SOUTH KOREA CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 196. SOUTH KOREA CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ENRICHMENT METHODS, 2018-2030 (USD MILLION)
• TABLE 197. SOUTH KOREA CIRCULATING TUMOR CELL MARKET SIZE, BY IMMUNOCAPTURE, 2018-2030 (USD MILLION)
• TABLE 198. SOUTH KOREA CIRCULATING TUMOR CELL MARKET SIZE, BY SIZE-BASED SEPARATION, 2018-2030 (USD MILLION)
• TABLE 199. SOUTH KOREA CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DIRECT DETECTION METHODS, 2018-2030 (USD MILLION)
• TABLE 200. SOUTH KOREA CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 201. SOUTH KOREA CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 202. SOUTH KOREA CIRCULATING TUMOR CELL MARKET SIZE, BY CLINICAL/ LIQUID BIOPSY, 2018-2030 (USD MILLION)
• TABLE 203. SOUTH KOREA CIRCULATING TUMOR CELL MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 204. TAIWAN CIRCULATING TUMOR CELL MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
• TABLE 205. TAIWAN CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 206. TAIWAN CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ENRICHMENT METHODS, 2018-2030 (USD MILLION)
• TABLE 207. TAIWAN CIRCULATING TUMOR CELL MARKET SIZE, BY IMMUNOCAPTURE, 2018-2030 (USD MILLION)
• TABLE 208. TAIWAN CIRCULATING TUMOR CELL MARKET SIZE, BY SIZE-BASED SEPARATION, 2018-2030 (USD MILLION)
• TABLE 209. TAIWAN CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DIRECT DETECTION METHODS, 2018-2030 (USD MILLION)
• TABLE 210. TAIWAN CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 211. TAIWAN CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 212. TAIWAN CIRCULATING TUMOR CELL MARKET SIZE, BY CLINICAL/ LIQUID BIOPSY, 2018-2030 (USD MILLION)
• TABLE 213. TAIWAN CIRCULATING TUMOR CELL MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 214. THAILAND CIRCULATING TUMOR CELL MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
• TABLE 215. THAILAND CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 216. THAILAND CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ENRICHMENT METHODS, 2018-2030 (USD MILLION)
• TABLE 217. THAILAND CIRCULATING TUMOR CELL MARKET SIZE, BY IMMUNOCAPTURE, 2018-2030 (USD MILLION)
• TABLE 218. THAILAND CIRCULATING TUMOR CELL MARKET SIZE, BY SIZE-BASED SEPARATION, 2018-2030 (USD MILLION)
• TABLE 219. THAILAND CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DIRECT DETECTION METHODS, 2018-2030 (USD MILLION)
• TABLE 220. THAILAND CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 221. THAILAND CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 222. THAILAND CIRCULATING TUMOR CELL MARKET SIZE, BY CLINICAL/ LIQUID BIOPSY, 2018-2030 (USD MILLION)
• TABLE 223. THAILAND CIRCULATING TUMOR CELL MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 224. VIETNAM CIRCULATING TUMOR CELL MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
• TABLE 225. VIETNAM CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 226. VIETNAM CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ENRICHMENT METHODS, 2018-2030 (USD MILLION)
• TABLE 227. VIETNAM CIRCULATING TUMOR CELL MARKET SIZE, BY IMMUNOCAPTURE, 2018-2030 (USD MILLION)
• TABLE 228. VIETNAM CIRCULATING TUMOR CELL MARKET SIZE, BY SIZE-BASED SEPARATION, 2018-2030 (USD MILLION)
• TABLE 229. VIETNAM CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DIRECT DETECTION METHODS, 2018-2030 (USD MILLION)
• TABLE 230. VIETNAM CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 231. VIETNAM CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 232. VIETNAM CIRCULATING TUMOR CELL MARKET SIZE, BY CLINICAL/ LIQUID BIOPSY, 2018-2030 (USD MILLION)
• TABLE 233. VIETNAM CIRCULATING TUMOR CELL MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 234. EUROPE, MIDDLE EAST & AFRICA CIRCULATING TUMOR CELL MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
• TABLE 235. EUROPE, MIDDLE EAST & AFRICA CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 236. EUROPE, MIDDLE EAST & AFRICA CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ENRICHMENT METHODS, 2018-2030 (USD MILLION)
• TABLE 237. EUROPE, MIDDLE EAST & AFRICA CIRCULATING TUMOR CELL MARKET SIZE, BY IMMUNOCAPTURE, 2018-2030 (USD MILLION)
• TABLE 238. EUROPE, MIDDLE EAST & AFRICA CIRCULATING TUMOR CELL MARKET SIZE, BY SIZE-BASED SEPARATION, 2018-2030 (USD MILLION)
• TABLE 239. EUROPE, MIDDLE EAST & AFRICA CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DIRECT DETECTION METHODS, 2018-2030 (USD MILLION)
• TABLE 240. EUROPE, MIDDLE EAST & AFRICA CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 241. EUROPE, MIDDLE EAST & AFRICA CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 242. EUROPE, MIDDLE EAST & AFRICA CIRCULATING TUMOR CELL MARKET SIZE, BY CLINICAL/ LIQUID BIOPSY, 2018-2030 (USD MILLION)
• TABLE 243. EUROPE, MIDDLE EAST & AFRICA CIRCULATING TUMOR CELL MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 244. EUROPE, MIDDLE EAST & AFRICA CIRCULATING TUMOR CELL MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 245. DENMARK CIRCULATING TUMOR CELL MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
• TABLE 246. DENMARK CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 247. DENMARK CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ENRICHMENT METHODS, 2018-2030 (USD MILLION)
• TABLE 248. DENMARK CIRCULATING TUMOR CELL MARKET SIZE, BY IMMUNOCAPTURE, 2018-2030 (USD MILLION)
• TABLE 249. DENMARK CIRCULATING TUMOR CELL MARKET SIZE, BY SIZE-BASED SEPARATION, 2018-2030 (USD MILLION)
• TABLE 250. DENMARK CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DIRECT DETECTION METHODS, 2018-2030 (USD MILLION)
• TABLE 251. DENMARK CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 252. DENMARK CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 253. DENMARK CIRCULATING TUMOR CELL MARKET SIZE, BY CLINICAL/ LIQUID BIOPSY, 2018-2030 (USD MILLION)
• TABLE 254. DENMARK CIRCULATING TUMOR CELL MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 255. EGYPT CIRCULATING TUMOR CELL MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
• TABLE 256. EGYPT CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 257. EGYPT CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ENRICHMENT METHODS, 2018-2030 (USD MILLION)
• TABLE 258. EGYPT CIRCULATING TUMOR CELL MARKET SIZE, BY IMMUNOCAPTURE, 2018-2030 (USD MILLION)
• TABLE 259. EGYPT CIRCULATING TUMOR CELL MARKET SIZE, BY SIZE-BASED SEPARATION, 2018-2030 (USD MILLION)
• TABLE 260. EGYPT CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DIRECT DETECTION METHODS, 2018-2030 (USD MILLION)
• TABLE 261. EGYPT CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 262. EGYPT CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 263. EGYPT CIRCULATING TUMOR CELL MARKET SIZE, BY CLINICAL/ LIQUID BIOPSY, 2018-2030 (USD MILLION)
• TABLE 264. EGYPT CIRCULATING TUMOR CELL MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 265. FINLAND CIRCULATING TUMOR CELL MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
• TABLE 266. FINLAND CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 267. FINLAND CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ENRICHMENT METHODS, 2018-2030 (USD MILLION)
• TABLE 268. FINLAND CIRCULATING TUMOR CELL MARKET SIZE, BY IMMUNOCAPTURE, 2018-2030 (USD MILLION)
• TABLE 269. FINLAND CIRCULATING TUMOR CELL MARKET SIZE, BY SIZE-BASED SEPARATION, 2018-2030 (USD MILLION)
• TABLE 270. FINLAND CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DIRECT DETECTION METHODS, 2018-2030 (USD MILLION)
• TABLE 271. FINLAND CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 272. FINLAND CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 273. FINLAND CIRCULATING TUMOR CELL MARKET SIZE, BY CLINICAL/ LIQUID BIOPSY, 2018-2030 (USD MILLION)
• TABLE 274. FINLAND CIRCULATING TUMOR CELL MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 275. FRANCE CIRCULATING TUMOR CELL MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
• TABLE 276. FRANCE CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 277. FRANCE CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ENRICHMENT METHODS, 2018-2030 (USD MILLION)
• TABLE 278. FRANCE CIRCULATING TUMOR CELL MARKET SIZE, BY IMMUNOCAPTURE, 2018-2030 (USD MILLION)
• TABLE 279. FRANCE CIRCULATING TUMOR CELL MARKET SIZE, BY SIZE-BASED SEPARATION, 2018-2030 (USD MILLION)
• TABLE 280. FRANCE CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DIRECT DETECTION METHODS, 2018-2030 (USD MILLION)
• TABLE 281. FRANCE CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 282. FRANCE CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 283. FRANCE CIRCULATING TUMOR CELL MARKET SIZE, BY CLINICAL/ LIQUID BIOPSY, 2018-2030 (USD MILLION)
• TABLE 284. FRANCE CIRCULATING TUMOR CELL MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 285. GERMANY CIRCULATING TUMOR CELL MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
• TABLE 286. GERMANY CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 287. GERMANY CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ENRICHMENT METHODS, 2018-2030 (USD MILLION)
• TABLE 288. GERMANY CIRCULATING TUMOR CELL MARKET SIZE, BY IMMUNOCAPTURE, 2018-2030 (USD MILLION)
• TABLE 289. GERMANY CIRCULATING TUMOR CELL MARKET SIZE, BY SIZE-BASED SEPARATION, 2018-2030 (USD MILLION)
• TABLE 290. GERMANY CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DIRECT DETECTION METHODS, 2018-2030 (USD MILLION)
• TABLE 291. GERMANY CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 292. GERMANY CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 293. GERMANY CIRCULATING TUMOR CELL MARKET SIZE, BY CLINICAL/ LIQUID BIOPSY, 2018-2030 (USD MILLION)
• TABLE 294. GERMANY CIRCULATING TUMOR CELL MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 295. ISRAEL CIRCULATING TUMOR CELL MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
• TABLE 296. ISRAEL CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 297. ISRAEL CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ENRICHMENT METHODS, 2018-2030 (USD MILLION)
• TABLE 298. ISRAEL CIRCULATING TUMOR CELL MARKET SIZE, BY IMMUNOCAPTURE, 2018-2030 (USD MILLION)
• TABLE 299. ISRAEL CIRCULATING TUMOR CELL MARKET SIZE, BY SIZE-BASED SEPARATION, 2018-2030 (USD MILLION)
• TABLE 300. ISRAEL CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DIRECT DETECTION METHODS, 2018-2030 (USD MILLION)
• TABLE 301. ISRAEL CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 302. ISRAEL CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 303. ISRAEL CIRCULATING TUMOR CELL MARKET SIZE, BY CLINICAL/ LIQUID BIOPSY, 2018-2030 (USD MILLION)
• TABLE 304. ISRAEL CIRCULATING TUMOR CELL MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 305. ITALY CIRCULATING TUMOR CELL MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
• TABLE 306. ITALY CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 307. ITALY CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ENRICHMENT METHODS, 2018-2030 (USD MILLION)
• TABLE 308. ITALY CIRCULATING TUMOR CELL MARKET SIZE, BY IMMUNOCAPTURE, 2018-2030 (USD MILLION)
• TABLE 309. ITALY CIRCULATING TUMOR CELL MARKET SIZE, BY SIZE-BASED SEPARATION, 2018-2030 (USD MILLION)
• TABLE 310. ITALY CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DIRECT DETECTION METHODS, 2018-2030 (USD MILLION)
• TABLE 311. ITALY CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 312. ITALY CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 313. ITALY CIRCULATING TUMOR CELL MARKET SIZE, BY CLINICAL/ LIQUID BIOPSY, 2018-2030 (USD MILLION)
• TABLE 314. ITALY CIRCULATING TUMOR CELL MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 315. NETHERLANDS CIRCULATING TUMOR CELL MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
• TABLE 316. NETHERLANDS CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 317. NETHERLANDS CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ENRICHMENT METHODS, 2018-2030 (USD MILLION)
• TABLE 318. NETHERLANDS CIRCULATING TUMOR CELL MARKET SIZE, BY IMMUNOCAPTURE, 2018-2030 (USD MILLION)
• TABLE 319. NETHERLANDS CIRCULATING TUMOR CELL MARKET SIZE, BY SIZE-BASED SEPARATION, 2018-2030 (USD MILLION)
• TABLE 320. NETHERLANDS CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DIRECT DETECTION METHODS, 2018-2030 (USD MILLION)
• TABLE 321. NETHERLANDS CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 322. NETHERLANDS CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 323. NETHERLANDS CIRCULATING TUMOR CELL MARKET SIZE, BY CLINICAL/ LIQUID BIOPSY, 2018-2030

The Circulating Tumor Cell Market was valued at USD 12.44 billion in 2023, expected to reach USD 14.17 billion in 2024, and is projected to grow at a CAGR of 13.99%, to USD 31.12 billion by 2030.

Circulating Tumor Cells (CTCs) offer a critical non-invasive biomarker that can significantly enhance cancer diagnostics, prognosis, and therapeutic efficacy predictions. The market for CTC analysis is driven by the urgent necessity for early cancer detection, personalized medicine, and disease monitoring applications, which hold particular promise given the shift towards precision medicine. End-use sectors like hospitals, diagnostic labs, and research institutions are pursuing CTC technologies for their potential to replace conventional biopsy methods. Key growth drivers include rising cancer prevalence, advances in detection technologies, and increased investment in research. The market is witnessing burgeoning opportunities in utilizing artificial intelligence for improved CTC detection and building comprehensive databases for predictive analytics. Nevertheless, challenges such as high costs, technical complexities, and standardization issues stand as significant barriers to market growth. Limited sensitivity and specificity of detection techniques remain a hurdle, often leading to under-detection or false positives. Furthermore, regulatory and ethical considerations significantly influence market dynamics, complicating approvals and market entry. Despite these challenges, innovation opportunities abound in developing cost-effective, highly sensitive detection methods and integrating multi-omics approaches for comprehensive insights. Innovations in microfluidics, nanotechnology, and molecular assay advancements are identified as promising areas that could propel market expansion. Moreover, fostering strategic collaborations across biotechnology firms, research entities, and healthcare providers could facilitate wider technology adoption and robust protocol development. Furthermore, the emergence of polymer-based capture substances and integrated platforms for disease management exemplify potential avenues for growth. Overall, the CTC market carries a dynamic nature characterized by rapid technological advancements and diverse application fields, but market sustainability will depend on addressing current limitations while harnessing new breakthroughs and forming partnerships that enhance clinical outcomes and market penetration. Market actors need to maintain agility to capitalize on these evolving opportunities.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Circulating Tumor Cell Market

The Circulating Tumor Cell Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increased spending in cancer-related therapies
  • Prevalence of cancer across the globe
  • Rising awareness and focus on early cancer detection
• Market Restraints
  • Lack of awareness about CTC systems
• Market Opportunities
  • Technological advancements in bioengineering and biomedical practices
  • Demand for minimally invasive diagnostics in recent years
• Market Challenges
  • Stringent government regulations for the approval of CTC technologies

Porter's Five Forces: A Strategic Tool for Navigating the Circulating Tumor Cell Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Circulating Tumor Cell Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Circulating Tumor Cell Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Circulating Tumor Cell Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Circulating Tumor Cell Market

A detailed market share analysis in the Circulating Tumor Cell Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Circulating Tumor Cell Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Circulating Tumor Cell Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Circulating Tumor Cell Market

A strategic analysis of the Circulating Tumor Cell Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Circulating Tumor Cell Market, highlighting leading vendors and their innovative profiles. These include BioFluidica, Biolidics Limited, Creatv MicroTech, Inc., Epic Sciences, Fluxion Biosciences, Inc., Greiner Bio One International GmbH, Ikonisys Inc., IVDiagnostics, LungLife AI, Inc., Menarini Silicon Biosystems, Miltenyi Biotec GmbH, NanoString Technologies, Inc., Precision Medicine Group, LLC, QIAGEN GmbH, Rarecells Diagnostics, ScreenCell, STEMCELL Technologies, Inc., Sysmex Corporation, and Vitatex, Inc.

Market Segmentation & Coverage

This research report categorizes the Circulating Tumor Cell Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Specimen, market is studied across Blood and Bone Marrow.
• Based on Technology, market is studied across CTC Analysis, CTC Detection & Enrichment Methods, and CTC Direct Detection Methods. The CTC Detection & Enrichment Methods is further studied across Combined Methods, Density-Based Separation, Immunocapture, and Size-Based Separation. The Immunocapture is further studied across Negative Selection and Positive Selection. The Size-Based Separation is further studied across Membrane-Based and Microfluidic-Based. The CTC Direct Detection Methods is further studied across Microscopy and SERS.
• Based on Product, market is studied across Blood Collection Tubes, Devices or Systems, and Kits & Reagents.
• Based on Application, market is studied across Clinical/ Liquid Biopsy and Research. The Clinical/ Liquid Biopsy is further studied across Risk Assessment and Screening & Monitoring. The Research is further studied across Cancer Stem Cell & Tumorigenesis Research and Drug or Therapy Development.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increased spending in cancer-related therapies
    • 5.1.1.2. Prevalence of cancer across the globe
    • 5.1.1.3. Rising awareness and focus on early cancer detection
  • 5.1.2. Restraints
    • 5.1.2.1. Lack of awareness about CTC systems
  • 5.1.3. Opportunities
    • 5.1.3.1. Technological advancements in bioengineering and biomedical practices
    • 5.1.3.2. Demand for minimally invasive diagnostics in recent years
  • 5.1.4. Challenges
    • 5.1.4.1. Stringent government regulations for the approval of CTC technologies
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Circulating Tumor Cell Market, by Specimen

• 6.1. Introduction
• 6.2. Blood
• 6.3. Bone Marrow

7. Circulating Tumor Cell Market, by Technology

• 7.1. Introduction
• 7.2. CTC Analysis
• 7.3. CTC Detection & Enrichment Methods
  • 7.3.1. Combined Methods
  • 7.3.2. Density-Based Separation
  • 7.3.3. Immunocapture
    • 7.3.3.1. Negative Selection
    • 7.3.3.2. Positive Selection
  • 7.3.4. Size-Based Separation
    • 7.3.4.1. Membrane-Based
    • 7.3.4.2. Microfluidic-Based
• 7.4. CTC Direct Detection Methods
  • 7.4.1. Microscopy
  • 7.4.2. SERS

8. Circulating Tumor Cell Market, by Product

• 8.1. Introduction
• 8.2. Blood Collection Tubes
• 8.3. Devices or Systems
• 8.4. Kits & Reagents

9. Circulating Tumor Cell Market, by Application

• 9.1. Introduction
• 9.2. Clinical/ Liquid Biopsy
  • 9.2.1. Risk Assessment
  • 9.2.2. Screening & Monitoring
• 9.3. Research
  • 9.3.1. Cancer Stem Cell & Tumorigenesis Research
  • 9.3.2. Drug or Therapy Development

10. Americas Circulating Tumor Cell Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Circulating Tumor Cell Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Circulating Tumor Cell Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. BioFluidica
• 2. Biolidics Limited
• 3. Creatv MicroTech, Inc.
• 4. Epic Sciences
• 5. Fluxion Biosciences, Inc.
• 6. Greiner Bio One International GmbH
• 7. Ikonisys Inc.
• 8. IVDiagnostics
• 9. LungLife AI, Inc.
• 10. Menarini Silicon Biosystems
• 11. Miltenyi Biotec GmbH
• 12. NanoString Technologies, Inc.
• 13. Precision Medicine Group, LLC
• 14. QIAGEN GmbH
• 15. Rarecells Diagnostics
• 16. ScreenCell
• 17. STEMCELL Technologies, Inc.
• 18. Sysmex Corporation
• 19. Vitatex, Inc